Overview
Geneticure is an innovative pharmacogenomics company based in Rochester, Minnesota, closely associated with the Mayo Clinic, an investor in the firm. The company focuses on utilizing genetic data to offer personalized medication plans, primarily targeting hypertension, a significant and preventable global health issue. Geneticure’s distinctive tests harness genetic insights to guide clinicians in selecting optimal treatments for chronic diseases, thereby minimizing the trial-and-error approach.
Business Model and Offerings
Geneticure's primary product is a personalized genetic test that evaluates 17 genotypes across 11 genes to assess an individual's response to various antihypertensive medications. The pharmacogenomic panel provided by Geneticure has demonstrated significant clinical efficacy, with potential reductions in systolic blood pressure by 22% and diastolic pressure by 39%. Additionally, it contributes to reduced risks of strokes and heart attacks by 40% and 25%, respectively. These tests support a more efficient chronic disease management strategy, enhancing treatment outcomes with fewer prescriptions and fewer office visits.
Leadership and Team
- Scott Snyder: Co-Founder and CEO
- Eric Snyder, PhD: COO
- Ryan Sprissler, PhD: CSO
- Thomas Olson, PhD: CCO
- Timothy Curry, MD, PhD: Medical Director
The leadership team at Geneticure comprises seasoned scientists and industry experts dedicated to advancing personalized medicine standards for chronic diseases.
Market Performance and Financials
Demonstrating a positive financial trajectory, Geneticure has successfully secured funding from major investors like Mayo Clinic Ventures and Wireframe Ventures. The company has reportedly raised between $4.4M and $5.96M across several funding rounds, indicating its potential for significant growth within the personalized medicine market.
Strategic Insights
Geneticure's partnerships with major health institutions and support from premier investors underline its technological and clinical promise. The firm is well-positioned to make a significant impact on hypertension treatment and is exploring broader applications in chronic disease management. They are also considering potential extensions to tackle other prevalent health challenges, such as COVID-19 treatment solutions.
Contact Information
- Location: 4 3rd Street SW, Suite 305b, Rochester, MN 55902
- Email: info@geneticure.com
- Phone: 1.800.DNA.8109
Further engagement with Geneticure can be facilitated via their [website](https://geneticure.com/), which provides resources such as testing information and insights into their continuing research initiatives.
Competitor Profiling
Key Competitors in the Industry
Geneticure competes within the personalized and precision medicine landscape, where several companies have established noteworthy presences.
Invitae Corporation
Invitae connects genomics with mainstream healthcare to enhance patient outcomes. Now part of Labcorp, the company offers comprehensive genetic testing services aimed at integrating genomic data into healthcare practices.
Color Health
Founded in 2013, Color Health specializes in accessible genetic testing addressing areas like hereditary cancer risk, cardiometabolic, cancer, and infectious diseases, promoting preventive healthcare accessibility and affordability.
23andMe
23andMe focuses on consumer genetics, offering direct-to-consumer DNA testing that provides insights into health, ancestry, and personal genetic traits, furthering participatory research to advance personalized healthcare.
Illumina Inc.
Illumina is recognized for leading genomic sequencing technologies, empowering large-scale genetic analysis across various fields, including oncology and reproductive health. The company’s efforts substantially support precision healthcare advancements.
Foundation Medicine
Foundation Medicine provides detailed genomic profiling services to support physician-guided treatment decisions, particularly in cancer care, with products like FoundationOne CDx, enabling targeted therapy alignment.
Market Position and Strategic Insights
Operating in a competitive environment characterized by the incorporation of genetic testing into routine healthcare, Geneticure’s focus on pharmacogenomics for chronic disease management sets it apart from competitors engaged in wide-ranging genetic analysis services. Drawing from its core genetic insights and strategic collaborations, Geneticure holds niche potential in tailoring therapies for chronic conditions, notably hypertension, whereas other competitors focus on broader genetic evaluations.
